The above results, combined with western blot, apoptosis, and cell cycle analyses, indicate that SPMI-HIF2-1 could kill cancer cells through a simultaneous atypical degradation of both MDM2 and MDMX and durable p53 activation. The gene discussed is TP53; the disease is cancer.